河北医科大学学报

• 论著 • 上一篇    下一篇

静脉应用rhBNP对急性前壁心肌梗死合并糖尿病患者肾功能的影响

  

  1. 河北医科大学第二医院心血管内五科,河北 石家庄 050000
  • 出版日期:2020-08-25 发布日期:2020-08-26
  • 作者简介:宋博超(1991-),男,河北文安人,河北医科大学第二医院医师,医学硕士,从事心脏病介入研究。
  • 基金资助:
    河北省直医疗卫生单位老年病防治研究(2016YFC1301104)

The effect of intravenous application of rhBNP on renal function in patients with acute anterior myocardial infarction complicated with diabetes

  1. Fifth Department of Cardiology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
  • Online:2020-08-25 Published:2020-08-26

摘要: 目的  探讨静脉应用重组人脑利钠肽(recombinant human brain natriuretic peptide,rhBNP)对急性前壁心肌梗死(acute anterior myocardial infarction, AAMI)合并糖尿病患者肾功能的影响。
方法  连续入选行急诊经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)治疗的AAMI合并糖尿病患者53例。随机分为rhBNP组25例和硝酸甘油(nitroglycerine,NIT)组28例。2组在直接PCI治疗后分别给予rhBNP和硝酸甘油泵入72 h。比较2组用药前和用药后24 h、72 h、7 d血清肌酐(serum creatinine, SCr)、胱抑素C(cystatin C, CysC)和估测肾小球滤过率(estimated glomerular filtration rate,eGFR)。比较2组用药前和用药后24 h、7 d尿量、左心室射血分数(left ventricular ejection fraction,LVEF)、二尖瓣舒张早期血流峰值(E)与二尖瓣环舒张早期运动速度(e′)比值(E/e′)。随访观察30 d内主要不良心脏事件发生情况。
结果  rhBNP组SCr、CysC水平呈先升高后降低趋势,eGFR呈先降低后升高趋势,用药后72 h时变化最明显,用药后7 d各项指标均恢复至接近基线水平。NIT组SCr、CysC、eGFR无明显改变。2组组间、时点间、组间·时点间交互作用差异有统计学意义(P<0.05)。用药后7 d ,2组24 h尿量均明显小于用药后24 h(P<0.05)。用药后7 d,rhBNP组LVEF水平高于用药后24 h,E/e′值低于用药后24 h,rhBNP组LVEF水平高于NIT组,E/e′值低于NIT组(P<0.05)。2组不良心脏事件发生率差异无统计学意义(P>0.05)。
结论  静脉应用rhBNP对AAMI合并糖尿病患者心功能有一定程度改善作用,对肾功能可能存在一过性损伤,短期内可恢复,总体安全有效。

关键词: 前壁心肌梗死;糖尿病;利钠肽,

Abstract: Objective  To investigate the effect of intravenous application of recombinant human brain natriuretic peptide(rhBNP) on renal function in patients with acute anterior myocardial infarction acute anterior myocardial infarction(AAMI) complicated with diabetes.
Methods  Fifty-three patients with AAMI combined with diabetes who underwent emergency percutaneous coronary intervention(PCI) were consecutively enrolled, and they were randomly divided into rhBNP group(n=25) and nitroglycerin group(NIT group, n=28). Two patients were given rhBNP and nitroglycerin for 72 h after direct percutaneous coronary intervention, respectively. Comparisons of levels of serum creatinine(SCr), cystatin C(CysC) and estimated glomerular filtration rate(eGFR) before and 24 hours, 72 hours and 7 days after medication were performed. Comparisons of urine volume, left ventricular ejection fraction(LVEF), early mitral valve diastolic blood flow peak(E) and early mitral annulus diastolic movement in both groups of patients before and 24 hours and 7 days after medication Speed(e′) ratio(E/e′) were also measured. The incidence of major adverse cardiac events(MACE) within 30 days was followed up.
Results  The levels of SCr and CysC in the rhBNP group increased firstly and then decreased, and the eGFR decreased firstly and then increased. The changes were most obvious at 72 h after treatment. All indexes returned to the baseline level 7 days after treatment. Levels of SCr and CysC, as well as levels of eGFR did not change significantly in the NIT group. There were statistically significant differences in the interaction between groups, time points, and groups·time points(P<0.05). At 7 days after medication, the urine output during 24 hours in both groups was significantly less than 24 hours after medication(P<0.05). At 7 days after treatment, the LVEF level in the rhBNP group was higher than 24 hours after treatment, and the E/e′ value was lower than 24 hours after the medication. The LVEF level in the rhBNP group was higher than that in the NIT group, and the E/e′ value was lower than that in the NIT group(P<0.05 ). There was no significant difference in the incidence of MACE between the 2 groups(P>0.05).
Conclusion  Intravenous administration of rhBNP may cause transient injury to renal function in patients with AAMI complicated with diabetes, but it could be restored in the short term with the improvement on the heart function.

Key words: anterior wall myocardial infarction, diabetes mellitus, natriuretic peptide, brain